Jefferies initiated coverage of Cabaletta Bio with a Buy rating and $36 price target. The analyst views the company as a leader in CART for autoimmune diseases. Data from all four of Cabaletta’s Phase 1/2s in 2024 ahead of competitors will be key near-term catalysts, and positive readouts could support an expedited regulatory path, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CABA:
- Cabaletta Bio’s CABA-201 Earns FDA Orphan Drug Status
- Cabaletta Bio Gets Orphan Drug Status for CABA-201 Therapy
- Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
- Cabaletta: FDA grants ODD to CABA-201 for myositis treatment
- Cabaletta Bio treatment of IIM granted FDA orphan designation
